Recombinant Microorganisms for MEG Production from Hexoses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing monoethylene glycol (MEG) and glycolic acid from hexose feedstocks face challenges such as inefficient xylose utilization, ATP shortages, excess NADH, low yield potential, and reliance on expensive and impure xylose feedstocks, as well as glucose-induced inhibition of xylose utilization.
Innovation Solution
The development of recombinant microorganisms with biosynthesis pathways that convert hexose feedstocks into pentose-5-phosphate intermediates, such as D-xylulose-5-phosphate, to produce MEG or glycolic acid, utilizing enzymes like transketolase, transaldolase, and ribulose-5-phosphate 3-epimerase, which bypass traditional glycolytic pathways and enable lossless conversion, thereby addressing yield and feedstock issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If xylose-based fermentative MEG production pathways are used, then MEG yield is improved, but feedstock availability and cost worsen due to expensive and impure xylose feedstocks
Solution Approach 1:
The patent uses glucose as an intermediary substrate that can be readily converted into pentose-5-phosphate intermediates (such as D-xylulose-5-phosphate) through engineered biosynthesis pathways. This intermediary approach allows the microorganism to access the high-yield xylose degradation pathway using abundant, inexpensive glucose feedstocks instead of costly xylose, thereby resolving the contradiction between yield improvement and feedstock accessibility
Solution Approach 2:
The patent fundamentally changes the substrate parameter from xylose to glucose, and alters the metabolic pathway parameters by introducing engineered biosynthesis routes that convert glucose through pentose-5-phosphate intermediates to MEG. This parameter transformation maintains the advantageous yield characteristics of xylose-based pathways while eliminating feedstock cost and availability constraints
2Ease of manufacture
If traditional glycolytic pathways are used for MEG production from hexoses, then feedstock utilization is simple, but product yield is reduced due to loss of yield potential and redox balance issues
Solution Approach 1:
The patent segments the traditional glycolytic pathway into distinct modules: (1) glucose uptake and phosphorylation, (2) engineered conversion to pentose-5-phosphate intermediates through transketolase and transaldolase reactions, and (3) MEG production from pentose-5-phosphate. This segmentation allows optimization of each stage, particularly enabling the high-yield conversion step through engineered pathways while maintaining overall process simplicity
Solution Approach 2:
The patent introduces pentose-5-phosphate intermediates (such as D-xylulose-5-phosphate) as key mediators that bridge glucose metabolism and MEG production. These intermediates serve as the critical connection point where engineered pathways diverge from traditional glycolysis to achieve superior yield while maintaining feedstock utilization efficiency
3Productivity
If xylose utilization pathways are engineered in microorganisms, then MEG production efficiency is improved, but ATP shortages and excess NADH worsen the redox balance
Solution Approach 1:
The patent changes the energy metabolism parameters by using glucose as the substrate, which provides more efficient ATP generation compared to xylose. The engineered pathway from glucose through pentose-5-phosphate to MEG is configured to maintain better redox balance, reducing excess NADH accumulation while preserving the high production efficiency characteristics of xylose-based pathways
4Ease of manufacture
If glucose is present in the feedstock, then feedstock availability is improved, but xylose utilization is inhibited by glucose-induced inhibition
Solution Approach 1:
Instead of attempting to use xylose directly (which suffers from glucose-induced inhibition), the patent inverts the approach by using glucose as the primary substrate and engineering pathways that convert glucose into the desired products. This inversion eliminates the inhibition problem entirely while maintaining feedstock availability advantages, as glucose is the more abundant and cheaper feedstock
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the yield and efficiency of MEG or glycolic acid production by utilizing readily available hexose sugars, minimizing ATP shortages, and overcoming the limitations of xylose-based processes, while providing a cost-effective and pure feedstock-independent solution.
Implementation Method 1
utilizing enzymes like transketolase, transaldolase, and ribulose-5-phosphate 3-epimerase
Implementation Method 2
utilizing enzymes like transketolase, transaldolase, and ribulose-5-phosphate 3-epimerase
Implementation Method 3
utilizing enzymes like transketolase, transaldolase, and ribulose-5-phosphate 3-epimerase
Implementation Method 4
recombinant microorganisms useful in the biosynthesis of monoethylene glycol or monoethylene glycol and one or more co-product from one or more hexose feedstock
Data Source
AI summary
The present application relates to recombinant microorganisms useful in the biosynthesis of monoethylene glycol (MEG), or optionally MEG and one or more co-product, from one or more hexose feedstock. The present application also relates to recombinant microorganisms useful in the biosynthesis of glycolic acid (GA), or optionally GA and one or more co-product, from one or more hexose feedstock. The present application relates to recombinant microorganisms useful in the biosynthesis of xylitol, or optionally xylitol and one or more co-product, from one or more hexose feedstock. Also provided are methods of producing MEG (or GA or xylitol), or optionally MEG (or GA or xylitol) and one or more co-product, from one or more hexose feedstock using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or the products MEG (or GA or xylitol), or optionally MEG (or GA or xylitol) and one or more co-product.